ETIFELMINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19N.ClH
Molecular Weight	273.8
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCC(CN)=C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=NFYYMNADTASPEE-UHFFFAOYSA-N

InChI=1S/C17H19N.ClH/c1-2-14(13-18)17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;/h3-12H,2,13,18H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	C17H19N
Molecular Weight	237.3395
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14254672

Gilutensin is a drug that was developed for the treatment of hypotensive circulatory disorders. As there is no information available on the drug since 1970, its development is supposed to be terminated in early phase.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypotensive circulatory disorders 3 Sources: http://www.ncbi.nlm.nih.gov/pubmed/14254672	Primary		Phase II 1147	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671199#sid=170465899	inconclusive [IC50 10.2188 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=170465899	yes [IC50 0.4772 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=170465899	yes [IC50 11.9877 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=170465899	yes [IC50 3.4671 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671197#sid=170465899	yes [IC50 4.3649 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671200#sid=170465899

PubMed

Title	Date	PubMed
[Gilutensin-Heptaminol in vegetative circulatory regulation disorders].	1970-10-23	5476058
[Hypotensive effect of gilutensin on surgical patients].	1968-11-03	5718353
[EXPERIENCES WITH GILUTENSIN IN CIRCULATORY DISORDERS].	1965-05	14294186
[THE TREATMENT OF HYPOTENSIVE CIRCULATORY DISORDERS WITH GILUTENSIN].	1964-08	14254672

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:29:37 GMT 2025` Edited by `admin` on `Mon Mar 31 19:29:37 GMT 2025`
Record UNII	01N5412224
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETIFELMINE HYDROCHLORIDE

Common Name

English

ETIFELMIN HYDROCHLORIDE

Preferred Name

English

2-DIPHENYLMETHYLENEBUTYLAMINE HYDROCHLORIDE

Systematic Name

English

ETIFELMINE HYDROCHLORIDE [JAN]

Common Name

English

ETIFELMIN HYDROCHLORIDE [MI]

Common Name

English

ETIFELMINE HYDROCHLORIDE [MART.]

Common Name

English

Etifelmin hydrochloride [WHO-DD]

Common Name

English

ETIFELMIN HCL

Common Name

English

Code System Code Type Description

PUBCHEM

121035